Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.41 |
| ▸ | CLK3 | P49761 | 8/20 | 0.41 |
| ▸ | CLK2 | P49760 | 7/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.40 |
| ▸ | WNT1 | P04628 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501695 | 0.88 | MAP3K5 (0.40) | MAP3K5DYRK1ACLK3CLK2MAP2K4 | |
| SCHEMBL5380936 | 0.82 | MAP3K5 (0.51) | PIM1MAP3K5DYRK1ACLK3CLK2 | |
| SCHEMBL6507804 | 0.78 | TTK (0.43) | MAP3K5DYRK1ACLK3CLK2MAP2K4 | |
| SCHEMBL6509704 | 0.73 | MAP2K4 (0.45) | PIM1MAP3K5DYRK1AMAP2K4 | |
| SCHEMBL5375071 | 0.69 | MAP3K5 (0.51) | MAP3K5DYRK1ACLK2MAP2K4WNT1 | |
| SCHEMBL6502512 | 0.69 | MAP2K4 (0.41) | MAP3K5DYRK1ACLK2MAP2K4 | |
| SCHEMBL362393 | 0.69 | F7 (0.52) | — | |
| SCHEMBL17594113 | 0.67 | ROCK2 (0.44) | PIM1 | |
| SCHEMBL3057993 | 0.67 | MKNK1 (0.50) | — | |
| SCHEMBL5380038 | 0.65 | MAPK1 (0.46) | MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | PIM1 172/4885MAP3K5 32/4885DYRK1A 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.